International Business Machines Corporation

Renesas Electronics Corporation

Hitachi Cable, Inc.

Fujitsu Corporation

Nec Corporation

Kyowa Hakko Kirin Co., Limited

Opnext Japan, Inc.

Nec Electronics Corporation

Yokogawa Electric Corporation

Kyowa Kirin Co., Ltd.

Nitto-Denko Corporation

Sega Corporation

Nec Compound Semiconductor Devices, Ltd.

Sony Magnescale Incorporation

Mitsubishi Heavy Industries Limited

Kenji Uchida

Koki Hirasawa

Daisuke Maruyama

Yoshio Horiuchi

Masaki Wakao

Akira Chinda

Nobuaki Miyamoto

Junichi Tanaka

Tsutomu Kubota

Satoshi Murata

Taku Sato

Seiji Ichikawa

Tomoaki Kimura

Tomoaki Hirokawa

Takeo Ogihara

Akira Miura

Toshiaki Kobayashi

Mamoru Mita

Akira Toyama

Yasushi Sakuma

Katsuya Ikezawa

Seiji Aratake

Kyoichiro Iida

Hiroyuki Kamiyama

Kenji Watanabe

Sanehiro Furuichi

Nobuyuki Suzuki

Naoyuki Sato

Sachio Suzuki

Hiroyuki Matsuura

Yoshihito Kobayashi

Yasuhiro Wada

Ryu Washino

Tadahiko Nakamura

Tsuyoshi Yakihara

Masashi Sakamoto

Shinya Ota

Hitoshi Arai

Yuichi Fukuda

Kazuo Nagaoka

Kimihisa Ueno

Tatsuya Ohtaka

Katsumi Shimada

Yasukazu Akasaka

Hiroyuki Hosoya

Yukihiro Iwasa

Yuka Sasaki

Yuichiro Hirano

Masatoshi Ohara

Takashi Imaeda

Seiji Sumi

Toshimi Kanai

Ryohei Kawai

Hideo Ikota

Masakazu Homma

Keiichi Shiraishi

Fumito Hiratani

Keisuke Yamamoto

Kei Yoshida

Yukihito Tsukumo

Reiya Takemura

Hideyuki Onodera

Sadao Wakabayashi

Hideharu Tsukamoto

Nobumasa Otsubo

Shinjiro Uenishi

Tatsuya Ishimori

Shuko Okazaki

Tsutomu Agatsuma

Setsuya Sasho

Toshihiko Kanasugi

Rina Nakamura

Masaru Mukaikubo

Kousuke Doi

Katsuya Motoda

Kazuhisa Kishino

Masakazu Honma

Kazuhiro Hibino

Kiyomi Ohkubo

Makoto Matumoto

Tsutomu Noguti

Hidenori Takada

Tomoichi Isobe

Tadahiko Shimano

Mitsuru Ohno

Takamichi Imaizumi

Kataro Shima

Maaki Wakao

Maasa Motosawa

Takahiro Kabeya

Masanori Tsuchimoto

Hura Harpreet Singh

Fumitake Takizawa

Yuichi Matsumoto

A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: (wherein, Land Lare the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).

Compound with anticancer activity

A navigation request is detected. The navigation request includes a destination for an autonomous vehicle from a starting location. A route is identified from the starting location to destination based on the navigation request. A regulator lookup is performed related to the route based on the navigation request. The regulator lookup is related to an owner of privacy data for one or more regulators. In response to the regulator lookup, a conditional allowance related to the route is received. The conditional allowance indicates that one or more autonomous vehicle sensors of the autonomous vehicle may not capture data related to a first property of a first regulator. the first property is located proximate to the route. The one or more autonomous vehicles sensors of the autonomous vehicle are restricted in response to the conditional allowance.

Substitute autonomous vehicle data

Aspects of the present invention disclose a method for assisting a stalled autonomous vehicle in an incommunicable area. The method includes one or more processors determining a route of an autonomous vehicle. The method further includes identifying an area of the route of the autonomous vehicle that includes a communication outage. The method further includes determining a driving difficulty of one or more segments of the route of the autonomous vehicle within the area. The method further includes determining a location of the autonomous vehicle within a segment of the one or more segments of the route based at least in part on the driving difficulty of the segment.

Stalled self-driving vehicle rescue system

A method for generating a visualization connection line is presented. The method may include displaying, by a processor, a plurality of nodes on a computer visualization, whereby each node within the displayed plurality of nodes includes a plurality of scoring targets. The method may also include calculating an importance score for each scoring target within the plurality of scoring targets. The method may further include determining a connection line path between at least two related nodes within the displayed plurality of nodes based on the calculated importance score. The method may also include displaying a visualization connection line on the computer visualization along the determined connection line path.

Increasing readability of visualization nodes

Cloning a local environment is described. Cloning a local environment can enable sharing the environment during pair programming. Cloning can have other uses as well. A server or other computer may maintain a clone environment of a first client apart from a second client such that the cloned computing environment, mimicking the environment of the first client, may be maintained on behalf of and used by a second client.

Sharing application local environment

In one embodiment, an information processing apparatus includes a calculation section, an identification section, and a notification section. The calculation section is configured to calculate similarity among a plurality of documents. The identification section is configured to identify, in response to a change made to a first document, a second document having a similarity greater than or equal to a first criterion as compared to the first document before the change. The notification section is configured to notify a user of the identified second document that the first document has been changed, in response to the change to the first document.

Tracking changes among similar documents

Supporting communications between developers of interdependent tasks of software parallel development can include inserting metadata, which expresses the existence of dependent code on which a first source code depends, into the first source code, at a time a first owner creates the first source code. A task to create the dependent code is created in response to detection of the metadata. Metadata expressing a second owner who owns the task of creating the dependent code and a status of the task is inserted into the first source code.

Software development support

The present invention provides a method of displaying nodes, including: displaying, in response to that one or more nodes are selected on a view screen on which nodes are displayed together with respective connection lines between the nodes, the selected one or more nodes on a pallet; drawing connection lines extending from the one or more nodes displayed on the pallet, on the view screen; and scrolling, in response to that one or more connection lines extending from the one or more nodes displayed on the pallet are selected or that one or more nodes on the pallet are selected, a display on the view screen such that one or more nodes at connection destinations of the selected connection lines or the selected nodes are displayed within the view screen.

Displaying nodes on a view screen

The present invention provides a heterocyclic compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof, in which X, R, Y, R, R, and Rare as defined herein. The compound of formula (I) inhibits a C-C chemokine receptor type 10 (CCR10) receptor and is useful as a prophylactic and/or therapeutic agent for skin diseases.

Substituted pyridines and pyridazines as CCR10 receptor inhibitors

The invention provides a pyridone compound represented by the following formula (I) [wherein, Rrepresents cycloalkyl optionally having substituent(s) and the like, Rrepresents a hydrogen atom and the like, Rrepresents hydroxy and the like, and Rrepresents the following formula (R-1) (wherein, Rand Rare the same or different and each represents a hydrogen atom and the like), and the like], or a pharmaceutically acceptable salt thereof, which is useful as a prophylactic and/or therapeutic agent for skin diseases, and the like. 

Pyridone compound

Growing community of inventors

Tokyo, Japan

Kenji Uchida